Calliditas Therapeutics AB banner

Intrinsic Value

The intrinsic value of Calliditas Therapeutics AB (CALT) under the Base Case is USD per share. Compared with the current market price of 40.0001 USD, the stock appears .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

CALT Intrinsic Value

What one share is worth in the bear, base and bull cases.

Create a free account · No card needed

Do our valuations actually work? See backtest results .

Alert me when CALT is below its intrinsic value
Today Hidden ·
CALT Valuation History

Intrinsic value next to the price over the past 4 years.

Create a free account · No card needed

Alternatives to CALT

Fundamental Analysis

What Calliditas Therapeutics AB Does

Pharmaceuticals Health Care

Calliditas Therapeutics AB, a biopharmaceutical company based in Sweden, has carved a niche for itself in the realm of specialty pharmaceuticals, particularly focusing on rare diseases. The company stands out with its dedication to developing novel treatments for orphan conditions that traditionally go under-addressed by larger pharmaceutical entities. Pivotal to its identity, Calliditas leverages its expertise in renal and hepatic diseases, emphasizing precision medicine aimed at improving the lives of patients with severe unmet medical conditions.

Headquarters
Sweden SE
Employees
65
IPO date
Jun 29, 2018
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue CALT Research

Decided on Calliditas Therapeutics? Get an email when CALT reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one CALT stock?

The intrinsic value for Calliditas Therapeutics AB (CALT) under the Base Case is USD.

Is CALT stock undervalued or overvalued?

Compared with the current market price of 40.0001 USD, the stock appears .

How reliable are our estimates? See how past valuations played out
Back to Top